Table 2.
Relationship of clinicopathologic factors for SLN metastasis.
| Variable | SLNM (n) | SLN-NM (n) | p Value | Hazard ratio | 95%CI |
|---|---|---|---|---|---|
| Age | |||||
| <40 years | 24 | 44 | |||
| ≥40 years | 72 | 277 | 0.009 | 2.098 | 1.198–3.677 |
| Menstrual status | |||||
| Premenopausal | 32 | 132 | |||
| Postmenopausal | 64 | 189 | 0.171 | 0.716 | 0.443–1.156 |
| BMI | |||||
| ≤25 | 58 | 215 | |||
| >25 | 38 | 106 | 0.235 | 0.753 | 0.470–1.205 |
| Family history | |||||
| Yes | 9 | 18 | |||
| No | 87 | 203 | 0.188 | 1.741 | 0.756–4.013 |
| Laterality of the tumor | |||||
| Left | 52 | 158 | |||
| Right | 44 | 163 | 0.392 | 1.219 | 0.772–1.926 |
| Tumor size | |||||
| ≤2 cm | 58 | 250 | |||
| >2 cm | 38 | 71 | 0.001 | 0.433 | 0.266–0.705 |
| Histological grade | |||||
| I–II | 62 | 270 | |||
| III | 34 | 51 | 0.000 | 0.344 | 0.206–0.576 |
| ER | |||||
| Positive | 76 | 232 | |||
| Negative | 20 | 89 | 0.178 | 1.458 | 0.841–2.526 |
| PR | |||||
| Positive | 68 | 222 | |||
| Negative | 28 | 99 | 0.754 | 1.083 | 0.657–1.785 |
| HER2 | |||||
| Positive | 16 | 60 | |||
| Negative | 80 | 261 | 0.652 | 0.870 | 0.475–1.594 |
| Ki67 | |||||
| Low index | 54 | 224 | |||
| High index | 42 | 97 | 0.014 | 0.557 | 0.349–0.889 |
| Molucular subtype | |||||
| Triple negative | 6 | 32 | |||
| Non-triple negative | 90 | 289 | 0.267 | 0.602 | 0.244–1.486 |
SLNM – sentinel lymphnode metastasis; SLN-NM – sentinel lymph node not metastasis; CI – confidence interval; ER – estrogen receptor; PR – progesterone receptor; HER2 – human epidermal growth factor receptor-2.